A Study to Evaluate the Efficacy and Safety of Infigratinib in Children and Adolescents With Achondroplasia
Abroad (travel likely)CompletedPHASE3
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Conditions
Achondroplasia
Locations
- QED Investigative Site, San Francisco, California, United States
- QED Investigative Site, Aurora, Colorado, United States
- QED Investigative Site, Baltimore, Maryland, United States
- QED Investigative Site, Columbia, Missouri, United States
- QED Investigative Site, Cincinnati, Ohio, United States
- QED Investigative Site, Nashville, Tennessee, United States
- QED Investigative Site, Madison, Wisconsin, United States
- QED Investigative Site, Buenos Aires, Buenos Aires F.D., Argentina
- QED Investigative Site, Parkville, Victoria, Australia
- QED Investigative Site, Edmonton, Alberta, Canada
- QED Investigative Site, London, Ontario, Canada
- QED Investigative Site, Ottawa, Ontario, Canada
- QED Investigative Site, Montreal, Quebec, Canada
- QED Investigative Site, Bron, France
- QED Investigative Site, Paris, France
- QED Investigative Site, Toulouse, France
- QED Investigative Site, Rome, Italy
- QED Investigative Site, Bergen, Norway
- QED Investigative Site, Oslo, Norway
- QED Investigative Site, Singapore, Singapore
- QED Investigative Site, Málaga, Spain
- QED Investigative Site, Vitoria-Gasteiz, Spain
- QED Investigative Site, Bristol, United Kingdom
- QED Investigative Site, Glasgow, United Kingdom
- QED Investigative Site, London, United Kingdom
- QED Investigative Site, Manchester, United Kingdom
- QED Investigative Site, Sheffield, United Kingdom